Proton-Pump Inhibitors lawsuit update

Verified snapshot

The facts that anchor this dossier

A plain-English, source-checked guide to the federal PPI kidney-injury litigation: what the medicines do, what plaintiffs allege, what the medical evidence can and cannot establish, and where MDL 2789 stands now.

Federal proceeding

MDL 2789

Centralized in the District of New Jersey before Judge Claire C. Cecchi.

Actions pending

11,321

JPML count as of July 1, 2026; this is a court inventory, not a claimant or settlement count.

Historical actions

18,706

Total actions historically associated with the MDL in the same JPML report.

Core allegation

Kidney injury

Filed complaints concern alleged acute interstitial nephritis, chronic kidney disease, renal failure, and related injuries after PPI use.

Evidence caution

Association is not individual causation

Observational studies can identify patterns but cannot, by themselves, prove why one person's kidney disease developed.

Documented chronology

How the litigation reached this point

What this litigation is really about

Proton-pump inhibitors, usually shortened to PPIs, reduce stomach-acid production. The category includes medicines sold under familiar names such as Nexium, Prilosec, Prevacid, and Protonix, along with generic equivalents. They are used for conditions including gastroesophageal reflux disease and erosive esophagitis. Their usefulness is not the issue the federal court is deciding. MDL 2789 coordinates product-liability cases in which plaintiffs allege that particular PPI manufacturers failed to give adequate warnings about kidney risks.

The JPML created this second PPI multidistrict litigation in August 2017 after the federal inventory grew to 161 actions and 34 potential tag-alongs. Its transfer order described alleged injuries including chronic kidney disease, acute interstitial nephritis, end-stage renal disease, and kidney failure. Those descriptions are allegations, not findings that every listed medicine caused every claimed injury. The manufacturers have been entitled to contest product identification, exposure, diagnosis, warning, causation, limitations, and damages case by case.

An MDL is a pretrial-management structure, not a class action and not a compensation program. Common discovery and legal motions can be handled once before the transferee judge, while an individual case may still turn on its own medical history and governing state law. The July 2026 count therefore says a great deal about docket size and very little about the merits or value of any one claim.

What the kidney evidence says — and does not say

Kidney concerns did not begin with the lawsuits. Acute tubulointerstitial nephritis, often called acute interstitial nephritis, appears in current PPI labeling. FDA's 2020 Protonix approval letter said the agency had identified safety information concerning subclinical acute or chronic interstitial nephritis that could lead to chronic renal inflammation and reduced renal function. The current warning tells clinicians to discontinue the medicine and evaluate a patient when acute TIN is suspected. That is a regulatory warning about a recognized adverse event, not a conclusion about any particular lawsuit.

The broader chronic-kidney-disease question is more complicated. The 2016 Lazarus study followed 10,482 ARIC participants and also analyzed a replication cohort. It reported that PPI use was associated with incident CKD. A separate VA study followed 173,321 new PPI users and 20,270 new H2-blocker users and likewise reported associations with several renal outcomes. Both are important epidemiology, but neither randomly assigned long-term PPI exposure. Residual confounding, differences in underlying illness, dose, treatment duration, and other medicines can affect observational results.

That distinction matters in human terms. A person can have a real kidney diagnosis and a history of PPI use without the records yet answering what caused the condition. Conversely, the absence of dramatic early symptoms does not rule out renal disease. Questions about stopping, switching, or monitoring a PPI belong with a prescribing clinician; abrupt self-directed changes can leave the underlying gastrointestinal condition untreated.

Where MDL 2789 stands

The litigation is mature but still enormous. The July 1, 2026 JPML report lists 11,321 pending actions and 18,706 historical actions. 'Historical' is the cumulative number associated with the docket; it does not mean 18,706 successful claims. 'Pending' likewise includes cases at different procedural stages and does not reveal how many have complete records, disputed product use, dispositive motions, or case-specific issues.

The public New Jersey court page continues to identify Judge Claire C. Cecchi as the presiding district judge and provides a repository of case-management orders. CMO 68, entered in January 2022, identified James Rieder, David Foster, and Freddy Bales for an anticipated bellwether sequence. A bellwether is a selected test case designed to inform the parties about recurring proof and trial issues. It does not bind every other plaintiff, and a schedule can change through rulings, dismissals, or party agreements.

Readers should be skeptical of pages that turn the current count into a settlement forecast. The JPML report contains no payment grid, filing deadline, average award, or eligibility rule. Any actual resolution terms would need to come from a filed court order, an authenticated agreement, or an official administrator—not a case-count trend.

The records that make the story specific

For someone trying to understand a possible case, the most useful chronology is usually concrete: the exact product and manufacturer; prescription and pharmacy dates; dose and duration; why the medicine was prescribed; baseline creatinine and estimated glomerular filtration rate; later kidney labs; nephrology notes; biopsy results if any; and competing explanations such as diabetes, hypertension, dehydration, infection, or other nephrotoxic medicines. Brand identification can matter because MDL 2789 includes several competitors and products with different histories.

Preserving records is different from drawing a medical conclusion. Pharmacy histories can clarify exposure, while longitudinal lab results can show when renal function changed. A clinician can address treatment and monitoring. A qualified lawyer can assess state-specific rules, including limitations periods and warning theories. This dossier does neither job and cannot tell a reader that a claim qualifies or predict an outcome.

The best way to follow the proceeding is to pair the monthly JPML count with signed orders on the District of New Jersey's MDL page. That prevents an old bellwether calendar or an undated marketing page from being mistaken for current law.

Reader questions

Frequently asked questions